|
pubmed:abstractText |
Osteoporosis is a well known side-effect of long-term treatment with glucocorticoids. However, the precise mechanism of this disorder is unclear. Recently, osteoprotegerin (OPG) [osteoclastogenesis inhibitory factor (OCIF)] has been identified as a novel cytokine, which inhibits differentiation and activation of osteoclast. In the present study, in order to clarify the roles of OPG in the development of glucocorticoid-induced osteoporosis, we measured circulating OPG before and after glucocorticoid therapy.
|
|
pubmed:affiliation |
Department of Nephrology, Jichi Medical School, Tochigi, Research Institute of Life Sciences, Snow Brand Milk Products Co., Ltd, Tochigi, Japan.
|
